Pfizer Inc. (NYSE:PFE) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 479,599 shares of the biopharmaceutical company’s stock after selling 16,994 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Pfizer were worth $13,808,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in shares of Pfizer during the third quarter valued at about $30,000. GoalVest Advisory LLC raised its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in Pfizer in the third quarter worth about $34,000. VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter worth about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 3.2 %

NYSE:PFE traded down $0.84 during mid-day trading on Thursday, hitting $25.43. 21,184,771 shares of the company’s stock were exchanged, compared to its average volume of 41,619,973. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The company has a 50 day simple moving average of $27.05 and a 200-day simple moving average of $28.50. The firm has a market capitalization of $144.00 billion, a P/E ratio of 71.14, a PEG ratio of 1.19 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PFE. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.